Loading...
XHKG
0954
Market cap22mUSD
Aug 07, Last price  
0.34HKD
1D
3.03%
1Q
17.24%
Jan 2017
-69.64%
IPO
-54.05%
Name

Changmao Biochemical Engineering Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
0.28
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
3.41%
Revenues
585m
-8.21%
93,041,986321,440,000397,420,000418,426,000385,302,000515,574,000620,233,000653,218,000703,032,000561,669,000514,779,000594,402,000630,841,000639,120,000494,580,000444,106,000547,976,000730,034,000637,078,000584,794,000
Net income
-68m
L-20.70%
34,973,36967,358,00034,648,00045,929,00043,203,00075,773,00041,105,00049,455,00069,992,00037,223,00045,274,00033,172,0003,382,00050,525,00058,299,00016,827,00058,318,00081,423,000-86,057,000-68,243,000
CFO
0k
P
25,519,58863,716,00019,802,00074,378,00087,674,00057,081,00044,543,00093,619,00068,584,00097,393,00071,919,00049,132,00065,781,00044,478,000118,327,00058,905,000-6,939,00019,633,000-2,349,0000
Dividend
May 22, 20230.086829 HKD/sh
Earnings
Aug 14, 2025

Profile

Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally. Its products include fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. The company is also involved in the research and development of medicine and nutraceutical products; production and sale of food additives; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou, the People's Republic of China.
URL
https://www.cmbec.com/
IPO date
Jun 28, 2002
Employees
574
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
584,794
-8.21%
637,078
-12.73%
730,034
33.22%
Cost of revenue
659,775
694,576
660,089
Unusual Expense (Income)
NOPBT
(74,981)
(57,498)
69,945
NOPBT Margin
9.58%
Operating Taxes
669
27,938
6,286
Tax Rate
8.99%
NOPAT
(75,650)
(85,436)
63,659
Net income
(68,243)
-20.70%
(86,057)
-205.69%
81,423
39.62%
Dividends
(42,332)
Dividend yield
13.78%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
515,415
243,162
138,222
Long-term debt
21,813
253,515
155,167
Deferred revenue
13,584
40
Other long-term liabilities
41,149
Net debt
462,663
400,121
229,760
Cash flow
Cash from operating activities
(2,349)
19,633
CAPEX
(139,169)
(223,519)
Cash from investing activities
(122,106)
(220,710)
Cash from financing activities
153,839
199,548
FCF
(108,014)
(240,261)
(197,431)
Balance
Cash
74,565
96,556
63,629
Long term investments
Excess cash
45,325
64,702
27,127
Stockholders' equity
583,339
460,288
589,101
Invested Capital
1,115,297
1,095,116
1,039,995
ROIC
9.71%
ROCE
6.55%
EV
Common stock shares outstanding
529,700
529,700
529,700
Price
0.58
-17.14%
0.70
2.94%
Market cap
307,226
-17.14%
370,790
2.94%
EV
707,248
600,912
EBITDA
(74,981)
(14,753)
102,147
EV/EBITDA
5.88
Interest
7,583
2,669
Interest/NOPBT
3.82%